

SCRI Trials and Trial Regimen Updates

The following updates were completed between Feb. 21, 2025, through March 21, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRliKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
24190	USOR 24190 LUN 571 Phase 3 Maintenance BMS-986012 or Atezolizumab Q28D USOR 24190 LUN 571 Phase 3 Induction BMS-986012 or Atezolizumab + Carboplatin + Etoposide D1-3 Q21D
24149	USOR 24149 LUN 572 Phase 3 Arm A Nivolumab/Relatlimab + Pemetrexed + Carboplatin Q21D USOR 24149 LUN 572 Phase 3 Arm A Nivolumab/Relatlimab + Pemetrexed + Cisplatin Q21D USOR 24149 LUN 572 Phase 3 Arm B Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 24149 LUN 572 Phase 3 Arm B Pembrolizumab + Pemetrexed + Cisplatin Q21D
24100	USOR 24100 GYN 133 Phase 2 Sapanisertib + Serabelisib + Paclitaxel Q28D

Study Number	Notes for New Build
23271	<p>USOR 23271 MEL 80 Phase 3 Randomized Nivolumab IV Week 21+ Q28D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Dacarbazine D1-5 Q21D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Nab-Paclitaxel D1,8,15 Q28D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Nivolumab + Relatlimab (Opdualag) Q28D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Nivolumab Monotherapy D1 or D1,15 Q28D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Paclitaxel Q21D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Pembrolizumab Q21D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Pembrolizumab Q42D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Physician's Choice Temozolomide D1-5 Q28D</p> <p>USOR 23271 MEL 80 Phase 3 Randomized Vusolimogene Oderparepvec (VO) ITU + Nivolumab IV Q14D</p> <p>USOR 23271 MEL 80 Phase 3 Vusolimogene Oderparepvec (VO) Additional Courses Q14D</p>
24312	<p>USOR 24312 LUN 567 Phase 2 Arm A BMS-986489 Q28D</p> <p>USOR 24312 LUN 567 Phase 2 Arm B Durvalumab Q28D</p>
24175	<p>USOR 24175 RM 1016 Phase 1 Part A FX-909 Q28D</p>
24112	<p>USOR 24112 GYN 136 Phase 2 TORL-1-23 Q21D</p>
24146	<p>USOR 24146 GI 384 Phase 3 Arm A RMC-6236 Q28D</p> <p>USOR 24146 GI 384 Phase 3 Arm B Liposomal Irinotecan (Nal-IRI) + Fluorouracil + Leucovorin Q28D</p> <p>USOR 24146 GI 384 Phase 3 Arm B Nab-paclitaxel + Gemcitabine (GnP) Q28D</p> <p>USOR 24146 GI 384 Phase 3 Arm B Oxaliplatin + Leucovorin + 5-fluorouracil (FOLFOX) Q28D</p> <p>USOR 24146 GI 384 Phase 3 Arm B Oxaliplatin + Leucovorin + Irinotecan + 5-fluorouracil (mFOLFIRINOX) Q28D</p>

Study Number	Notes for New Build
24151	USOR 24151 BRE 444 Phase 3 Elacestrant Q28D USOR 24151 BRE 444 Phase 3 SoC Endocrine Therapy Q28D
24171	USOR 24171 LUN 586 Phase 3 Rilvegostomig or Pembrolizumab + Pemetrexed + Carboplatin fb Rilvegostomig or Pembrolizumab + Pemetrexed Q21D USOR 24171 LUN 586 Phase 3 Rilvegostomig or Pembrolizumab + Pemetrexed + Cisplatin fb Rilvegostomig or Pembrolizumab + Pemetrexed Q21D

Updated Reference Information

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
23294	Version 020-04: 12 Dec 2024.	NA	NA	Updated drug instruction to include weight-based dosing and stability
22320	Version 3.0: 09 July 2024	NA	Updated observation time	NA
24073	Amendment 4/US-2: 18 Dec 2024.	NA	NA	Combined Cycle 1 and 2+ regimens. Separated Part 1 and Part 2 regimens.
24018	Version 2.0: 24 Oct 2024.	NA	NA	NA
23247	Version 4.0: 23 Sep 2024.	NA	NA	Added SoC substitutions
22333	Amendment 4 Version 5: 29 Nov 2024	NA	NA	NA

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
22297	Version 3.0: 22 July 2024.	NA	NA	Corrected regimen schedule
24093	NA	NA	NA	Updated IP name.
24010	NA	NA	NA	Updated Venetoclax dispensation schedule
23099	Amendment 02: 19 Dec 2024.	NA	Updated premedication wording	NA
23223	Added: Local Amendment 4.0: 18 Dec 2024.	NA	NA	NA
20266	Version 6.1: 20 Dec 2024.	NA	NA	NA
21181	Amendment 4: 14 Nov 2024.	NA	NA	NA
22333	Amendement 5 (Version 6): 21 Jan 2025.	NA	NA	NA
23228	Version 4.0: 12 November 2024	NA	Updated prophylaxis. Added BSA wording.	NA
23156	Version 4.0: 01OCT2024.	Updated cycle length	Update administration duration	Added additional administration schedule.
21498	Version 5.0: 13 Sep 2024.	NA	NA	NA